BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: de Masson A, Beylot-Barry M, Bouaziz JD, Peffault de Latour R, Aubin F, Garciaz S, d’Incan M, Dereure O, Dalle S, Dompmartin A. Allogeneic stem cell transplantation for advanced cutaneous T-cell lymphomas: a study from the French Society of Bone Marrow Transplantation and French Study Group on Cutaneous Lymphomas. Haematologica. 2014;99:527-534. [PMID: 24213148 DOI: 10.3324/haematol.2013.098145] [Cited by in Crossref: 59] [Cited by in F6Publishing: 60] [Article Influence: 5.9] [Reference Citation Analysis]
Number Citing Articles
1 Peru S, Prochazkova-Carlotti M, Cherrier F, Velazquez J, Richard E, Idrissi Y, Cappellen D, Azzi-Martin L, Pham-Ledard A, Beylot-Barry M, Merlio JP, Poglio S. Cutaneous Lymphocyte Antigen Is a Potential Therapeutic Target in Cutaneous T-Cell Lymphoma. J Invest Dermatol 2022;142:3243-3252.e10. [PMID: 35850209 DOI: 10.1016/j.jid.2022.06.016] [Reference Citation Analysis]
2 Elliott J, Ahlawat S, Prince HM, Kennedy G, Wells J, Huang G, Collins J, Bardy P, Van Der Weyden C, Ritchie D, Khot A. Long-term outcomes for allogeneic bone marrow transplantation in Sezary syndrome and mycosis fungoides. Bone Marrow Transplant 2022. [PMID: 36028756 DOI: 10.1038/s41409-022-01787-3] [Reference Citation Analysis]
3 Canu D, Beylot-barry M, Ingen-housz-oro S, Ouhabrache N, To N. Place de la radiothérapie dans le traitement des lymphomes cutanés. Annales de Dermatologie et de Vénéréologie - FMC 2022;2:238-244. [DOI: 10.1016/j.fander.2021.08.006] [Reference Citation Analysis]
4 de Masson A. New biotherapies for the treatment of cutaneous T-cell lymphomas. Presse Med 2022;:104110. [PMID: 35026391 DOI: 10.1016/j.lpm.2022.104110] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Kim YH. What factors guide treatment selection in mycosis fungoides and Sezary syndrome? Hematology Am Soc Hematol Educ Program 2021;2021:303-12. [PMID: 34889422 DOI: 10.1182/hematology.2021000263] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
6 Kawana Y, Suga H, Kamijo H, Miyagaki T, Sugaya M, Sato S. Roles of OX40 and OX40 Ligand in Mycosis Fungoides and Sézary Syndrome. Int J Mol Sci 2021;22:12576. [PMID: 34830466 DOI: 10.3390/ijms222212576] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Dummer R, Vermeer MH, Scarisbrick JJ, Kim YH, Stonesifer C, Tensen CP, Geskin LJ, Quaglino P, Ramelyte E. Cutaneous T cell lymphoma. Nat Rev Dis Primers 2021;7:61. [PMID: 34446710 DOI: 10.1038/s41572-021-00296-9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 19] [Article Influence: 7.5] [Reference Citation Analysis]
8 Weng WK, Arai S, Rezvani A, Johnston L, Lowsky R, Miklos D, Shizuru J, Muffly L, Meyer E, Negrin RS, Wang E, Almazan T, Million L, Khodadoust M, Li S, Hoppe RT, Kim YH. Nonmyeloablative allogeneic transplantation achieves clinical and molecular remission in cutaneous T-cell lymphoma. Blood Adv 2020;4:4474-82. [PMID: 32941647 DOI: 10.1182/bloodadvances.2020001627] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
9 de Masson A, Peffault de Latour R, Ram-wolff C, Bagot M. Traitement des lymphomes T cutanés par allogreffe de cellules souches hématopoïétiques. Annales de Dermatologie et de Vénéréologie - FMC 2021;1:187-192. [DOI: 10.1016/j.fander.2020.07.004] [Reference Citation Analysis]
10 de Masson A, Ram-wolff C, Bagot M. Biomédicaments dans le traitement des lymphomes T cutanés. Annales de Dermatologie et de Vénéréologie - FMC 2021;1:122-127. [DOI: 10.1016/j.fander.2020.05.007] [Reference Citation Analysis]
11 Prince HM, Abeyakoon C. Allogeneic haematopoietic stem cell transplantation for advanced stage mycosis fungoides and Sézary syndrome: never-late, never-never? Bone Marrow Transplant 2021;56:1232-4. [PMID: 33526916 DOI: 10.1038/s41409-020-01150-4] [Reference Citation Analysis]
12 Domingo-Domenech E, Duarte RF, Boumedil A, Onida F, Gabriel I, Finel H, Arcese W, Browne P, Beelen D, Kobbe G, Veelken H, Arranz R, Greinix H, Lenhoff S, Poiré X, Ribera JM, Thompson J, Zuckerman T, Mufti GJ, Cortelezzi A, Olavarria E, Dreger P, Sureda A, Montoto S. Allogeneic hematopoietic stem cell transplantation for advanced mycosis fungoides and Sézary syndrome. An updated experience of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant 2021;56:1391-401. [PMID: 33420392 DOI: 10.1038/s41409-020-01197-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
13 Ingen-housz-oro S, d’Incan M, Beylot-barry M. Mycosis fongoïde et lymphomes T érythrodermiques. Annales de Dermatologie et de Vénéréologie - FMC 2021;1:40-47. [DOI: 10.1016/j.fander.2020.06.004] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Bhabha FK, McCormack C, Wells J, Campbell BA, Newland K, Lade S, Buelens O, Joske D, Shortt J, Mapp S, Radeski D, Hertzberg M, Khot A, Van Der Weyden C, Khoo C, Hawkes E, Prince HM. Mycosis fungoides and Sézary syndrome: Australian clinical practice statement. Australas J Dermatol 2021;62:e8-e18. [PMID: 33368169 DOI: 10.1111/ajd.13467] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
15 Brouwer IJ, Out-Luiting JJ, Vermeer MH, Tensen CP. Cucurbitacin E and I target the JAK/STAT pathway and induce apoptosis in Sézary cells. Biochem Biophys Rep 2020;24:100832. [PMID: 33102814 DOI: 10.1016/j.bbrep.2020.100832] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
16 Dumont M, Peffault de Latour R, Ram-Wolff C, Bagot M, de Masson A. Allogeneic Hematopoietic Stem Cell Transplantation in Cutaneous T-Cell Lymphomas. Cancers (Basel) 2020;12:E2856. [PMID: 33023002 DOI: 10.3390/cancers12102856] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
17 Sézary syndrome. Skin Lymphoma 2020. [DOI: 10.1002/9781119485933.ch4] [Reference Citation Analysis]
18 Dimitriou F, Schanz U, Nair G, Kimeswenger S, Brüggen MC, Hoetzenecker W, French LE, Dummer R, Cozzio A, Guenova E. Long-Term Disease Control After Allogeneic Hematopoietic Stem Cell Transplantation in Primary Cutaneous T-Cell Lymphoma; Results From a Single Institution Analysis. Front Med (Lausanne) 2020;7:290. [PMID: 32714935 DOI: 10.3389/fmed.2020.00290] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
19 Dangien A, Ram-Wolff C, Brice P, Battistella M, Roelens M, Moins-Teisserenc H, Peffault de Latour R, Mourah S, Bouaziz JD, Lebbé C, Bagot M, de Masson A. Ifosfamide and etoposide in advanced-stage, relapsed or refractory primary cutaneous T-cell lymphomas. Br J Dermatol 2020;183:961-2. [PMID: 32407544 DOI: 10.1111/bjd.19220] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
20 . Mycosis fungoides. Skin Lymphoma. Wiley; 2020. pp. 23-112. [DOI: 10.1002/9781119485933.ch3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
21 Isufi I, Seropian S, Gowda L, Wilson LD, Roberts K, Girardi M, Perreault S, Foss F. Outcomes for allogeneic stem cell transplantation in refractory mycosis fungoides and primary cutaneous gamma Delta T cell lymphomas. Leukemia & Lymphoma 2020;61:2955-61. [DOI: 10.1080/10428194.2020.1790555] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
22 Dalal M, Mitchell S, Mccloskey C, Zagadailov E, Gautam A. The clinical and humanistic burden of cutaneous T-cell lymphomas and response to conventional and novel therapies: results of a systematic review. Expert Review of Hematology 2020;13:405-19. [DOI: 10.1080/17474086.2020.1717945] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
23 Babakoohi S. Cutaneous T Cell Lymphoma: Ready to Enter the World of Allogeneic Transplant? Biol Blood Marrow Transplant 2020;26:e5-6. [PMID: 31733298 DOI: 10.1016/j.bbmt.2019.11.009] [Reference Citation Analysis]
24 Bagot M. Données récentes sur la physiopathologie et les approches thérapeutiques des lymphomes T cutanés épidermotropes. Bulletin de l'Académie Nationale de Médecine 2019;203:701-705. [DOI: 10.1016/j.banm.2019.10.003] [Reference Citation Analysis]
25 Martinez XU, Di Raimondo C, Abdulla FR, Zain J, Rosen ST, Querfeld C. Leukaemic variants of cutaneous T-cell lymphoma: Erythrodermic mycosis fungoides and Sézary syndrome. Best Pract Res Clin Haematol 2019;32:239-52. [PMID: 31585624 DOI: 10.1016/j.beha.2019.06.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
26 de Masson A, O'Malley JT, Elco CP, Garcia SS, Divito SJ, Lowry EL, Tawa M, Fisher DC, Devlin PM, Teague JE, Leboeuf NR, Kirsch IR, Robins H, Clark RA, Kupper TS. High-throughput sequencing of the T cell receptor β gene identifies aggressive early-stage mycosis fungoides. Sci Transl Med 2018;10:eaar5894. [PMID: 29743350 DOI: 10.1126/scitranslmed.aar5894] [Cited by in Crossref: 69] [Cited by in F6Publishing: 67] [Article Influence: 17.3] [Reference Citation Analysis]
27 Dai J, Almazan TH, Hong EK, Khodadoust MS, Arai S, Weng WK, Kim YH. Potential Association of Anti-CCR4 Antibody Mogamulizumab and Graft-vs-Host Disease in Patients With Mycosis Fungoides and Sézary Syndrome. JAMA Dermatol 2018;154:728-30. [PMID: 29800117 DOI: 10.1001/jamadermatol.2018.0884] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
28 Dumont M, Ram‐wolff C, Roelens M, Brice P, Peffault de Latour R, Battistella M, Madelaine I, Delyon J, Herms F, Bouaziz J, Moins‐teisserenc H, Lebbé C, Bagot M, Masson A. Efficacy and safety of brentuximab vedotin plus bendamustine in advanced‐stage primary cutaneous T‐cell lymphomas. Br J Dermatol 2019;181:1315-7. [DOI: 10.1111/bjd.18215] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
29 Specht L, Skov L. Cutaneous Lymphomas. Clin Oncol (R Coll Radiol) 2019;31:797-807. [PMID: 31405542 DOI: 10.1016/j.clon.2019.07.018] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
30 Shanbhag S, Wagner-Johnston N, Ambinder RF, Jones RJ. Is It Time to Revisit the Role of Allogeneic Transplantation in Lymphoma? Curr Oncol Rep 2019;21:65. [PMID: 31183579 DOI: 10.1007/s11912-019-0809-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
31 Mahévas T, Ram‐wolff C, Battistella M, Pennamen M, Rivet J, Brice P, Bagot M. Dramatic response to brentuximab vedotin in refractory nontransformed CD 30 mycosis fungoides allowing allogeneic stem cell transplant and long‐term complete remission. Br J Dermatol 2019;180:1517-20. [DOI: 10.1111/bjd.17254] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
32 Dereure O. [Primary skin lymphomas: Current therapy]. Ann Dermatol Venereol 2019;146:92-9. [PMID: 30709635 DOI: 10.1016/j.annder.2018.11.012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
33 Narra RK, Shah NN. Allogenic Transplant for Non-Hodgkin Lymphoma. Hematopoietic Cell Transplantation for Malignant Conditions 2019. [DOI: 10.1016/b978-0-323-56802-9.00015-8] [Reference Citation Analysis]
34 Demina OM, Akilov OE, Rumyantsev AG. Cutaneous T-cell lymphomas: modern data of pathogenesis, clinics and therapy. Onkogematologiâ 2018;13:25-38. [DOI: 10.17650/1818-8346-2018-13-3-25-38] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
35 Friedrichs B, Stelljes M, Schmitz N. The role of allogeneic stem cell transplantation in T-cell lymphoma. Current Opinion in Oncology 2018;30:301-7. [DOI: 10.1097/cco.0000000000000473] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
36 Scarisbrick J. Staging of Mycosis Fungoides and Sézary Syndrome: Time for an Update? EMJ Hematol 2018. [DOI: 10.33590/emjhematol/10313097] [Reference Citation Analysis]
37 Méchineaud M, Mercier M, Le Corre Y, Croué A, Ifrah N, Martin L. Lymphome T cutané et systémique traité avec succès par greffe haplo-identique. Annales de Dermatologie et de Vénéréologie 2018;145:439-44. [DOI: 10.1016/j.annder.2018.02.016] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
38 Schmitz N, Lenz G, Stelljes M. Allogeneic hematopoietic stem cell transplantation for T-cell lymphomas. Blood 2018;132:245-53. [PMID: 29699989 DOI: 10.1182/blood-2018-01-791335] [Cited by in Crossref: 37] [Cited by in F6Publishing: 40] [Article Influence: 7.4] [Reference Citation Analysis]
39 Cudillo L, Cerretti R, Picardi A, Mariotti B, De Angelis G, Cantonetti M, Postorino M, Ceresoli E, De Santis G, Nasso D, Pisani F, Scala E, Di Piazza F, Lanti A; William Arcese for the Rome Transplant Network. Allogeneic hematopoietic stem cell transplantation in Primary Cutaneous T Cell Lymphoma. Ann Hematol 2018;97:1041-8. [PMID: 29442161 DOI: 10.1007/s00277-018-3275-z] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
40 Janiga J, Kentley J, Nabhan C, Abdulla F. Current systemic therapeutic options for advanced mycosis fungoides and Sézary syndrome. Leuk Lymphoma 2018;59:562-77. [PMID: 29308723 DOI: 10.1080/10428194.2017.1347650] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
41 Berg S, Villasenor-Park J, Haun P, Kim EJ. Multidisciplinary Management of Mycosis Fungoides/Sézary Syndrome. Curr Hematol Malig Rep 2017;12:234-43. [PMID: 28540671 DOI: 10.1007/s11899-017-0387-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
42 Stranzenbach R, Theurich S, Schlaak M. [Role of stem cell transplantation in treatment of primary cutaneous T‑cell lymphoma]. Hautarzt 2017;68:716-20. [PMID: 28785925 DOI: 10.1007/s00105-017-4023-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
43 Heitmiller K, Barnes J, Chen ST. Cutaneous Lymphoma—Inpatient Considerations. Curr Derm Rep 2017;6:63-76. [DOI: 10.1007/s13671-017-0173-x] [Reference Citation Analysis]
44 Atilla E, Atilla PA, Bozdag SC, Yuksel MK, Toprak SK, Topcuoglu P, Akay BN, Sanli H, Gurman G, Ozcan M. Allogeneic hematopoietic stem cell transplantation for refractory mycosis fungoides (MF) and Sezary syndrome (SS). Int J Hematol 2017;106:426-30. [DOI: 10.1007/s12185-017-2245-x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
45 Trautinger F, Eder J, Assaf C, Bagot M, Cozzio A, Dummer R, Gniadecki R, Klemke C, Ortiz-romero PL, Papadavid E, Pimpinelli N, Quaglino P, Ranki A, Scarisbrick J, Stadler R, Väkevä L, Vermeer MH, Whittaker S, Willemze R, Knobler R. European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome – Update 2017. European Journal of Cancer 2017;77:57-74. [DOI: 10.1016/j.ejca.2017.02.027] [Cited by in Crossref: 260] [Cited by in F6Publishing: 202] [Article Influence: 43.3] [Reference Citation Analysis]
46 Hoppe RT, Kim YH, Advani RH. Mycosis Fungoides and Sézary Syndrome. Holland-Frei Cancer Medicine 2017. [DOI: 10.1002/9781119000822.hfcm121] [Reference Citation Analysis]
47 Scarisbrick JJ. Cutaneous T-cell lymphomas: an urgent need for more improved therapies. Br J Dermatol 2016;175:14-5. [PMID: 27484267 DOI: 10.1111/bjd.14608] [Reference Citation Analysis]
48 Patir P, Vural F. Treatment of mycosis fungoides, in the era of stem cell transplantation. World J Dermatol 2016; 5(1): 52-56 [DOI: 10.5314/wjd.v5.i1.52] [Reference Citation Analysis]
49 Zain J, Thomas SH. Hematopoietic Cell Transplantation for Non'Hodgkin Lymphoma (T Cell). Thomas’ Hematopoietic Cell Transplantation 2016. [DOI: 10.1002/9781118416426.ch58] [Reference Citation Analysis]
50 Hughey LC. Practical Management of CD30⁺ Lymphoproliferative Disorders. Dermatol Clin 2015;33:819-33. [PMID: 26433852 DOI: 10.1016/j.det.2015.05.013] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
51 Virmani P, Zain J, Rosen ST, Myskowski PL, Querfeld C. Hematopoietic Stem Cell Transplant for Mycosis Fungoides and Sézary Syndrome. Dermatologic Clinics 2015;33:807-18. [DOI: 10.1016/j.det.2015.05.014] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 4.0] [Reference Citation Analysis]
52 Hosing C, Bassett R, Dabaja B, Talpur R, Alousi A, Ciurea S, Popat U, Qazilbash M, Shpall EJ, Oki Y, Nieto Y, Pinnix C, Fanale M, Maadani F, Donato M, Champlin R, Duvic M. Allogeneic stem-cell transplantation in patients with cutaneous lymphoma: updated results from a single institution. Ann Oncol 2015;26:2490-5. [PMID: 26416896 DOI: 10.1093/annonc/mdv473] [Cited by in Crossref: 67] [Cited by in F6Publishing: 69] [Article Influence: 8.4] [Reference Citation Analysis]
53 Jacobsen ED. Stem cell transplantation for mycosis fungoides/Sézary syndrome. Clinical Guide to Transplantation in Lymphoma 2015. [DOI: 10.1002/9781118863282.ch23] [Reference Citation Analysis]
54 Vermeer MH, Willemze R. Limited effect of chemotherapy in cutaneous lymphoma. Blood 2015;125:4-5. [DOI: 10.1182/blood-2014-11-609305] [Reference Citation Analysis]
55 Shiratori S, Fujimoto K, Nishimura M, Hatanaka KC, Kosugi-kanaya M, Okada K, Sugita J, Shigematsu A, Hashimoto D, Endo T, Kondo T, Abe R, Hashino S, Matsuno Y, Shimizu H, Teshima T. Allogeneic hematopoietic stem cell transplantation following reduced-intensity conditioning for mycosis fungoides and Sezary syndrome: RIC-HSCT for MF/SS. Hematol Oncol 2016;34:9-16. [DOI: 10.1002/hon.2162] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
56 Duarte RF, Boumendil A, Onida F, Gabriel I, Arranz R, Arcese W, Poiré X, Kobbe G, Narni F, Cortelezzi A. Long-term outcome of allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sézary syndrome: a European society for blood and marrow transplantation lymphoma working party extended analysis. J Clin Oncol. 2014;32:3347-3348. [PMID: 25154828 DOI: 10.1200/jco.2014.57.5597] [Cited by in Crossref: 65] [Cited by in F6Publishing: 68] [Article Influence: 7.2] [Reference Citation Analysis]
57 Lechowicz MJ, Lazarus HM, Carreras J, Laport GG, Cutler CS, Wiernik PH, Hale GA, Maharaj D, Gale RP, Rowlings PA. Allogeneic hematopoietic cell transplantation for mycosis fungoides and Sezary syndrome. Bone Marrow Transplant. 2014;49:1360-1365. [PMID: 25068422 DOI: 10.1038/bmt.2014.161] [Cited by in Crossref: 66] [Cited by in F6Publishing: 70] [Article Influence: 7.3] [Reference Citation Analysis]